• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对用于评估由一个或多个感兴趣事件组成的事件发生时间替代终点的两阶段元分析Copula建模方法的研究。

An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest.

作者信息

Dimier Natalie, Todd Susan

机构信息

Roche Products Ltd, Welwyn Garden City, UK.

Department of Mathematics and Statistics, University of Reading, Reading, UK.

出版信息

Pharm Stat. 2017 Sep;16(5):322-333. doi: 10.1002/pst.1812. Epub 2017 May 19.

DOI:10.1002/pst.1812
PMID:28544622
Abstract

Clinical trials of experimental treatments must be designed with primary endpoints that directly measure clinical benefit for patients. In many disease areas, the recognised gold standard primary endpoint can take many years to mature, leading to challenges in the conduct and quality of clinical studies. There is increasing interest in using shorter-term surrogate endpoints as substitutes for costly long-term clinical trial endpoints; such surrogates need to be selected according to biological plausibility, as well as the ability to reliably predict the unobserved treatment effect on the long-term endpoint. A number of statistical methods to evaluate this prediction have been proposed; this paper uses a simulation study to explore one such method in the context of time-to-event surrogates for a time-to-event true endpoint. This two-stage meta-analytic copula method has been extensively studied for time-to-event surrogate endpoints with one event of interest, but thus far has not been explored for the assessment of surrogates which have multiple events of interest, such as those incorporating information directly from the true clinical endpoint. We assess the sensitivity of the method to various factors including strength of association between endpoints, the quantity of data available, and the effect of censoring. In particular, we consider scenarios where there exist very little data on which to assess surrogacy. Results show that the two-stage meta-analytic copula method performs well under certain circumstances and could be considered useful in practice, but demonstrates limitations that may prevent universal use.

摘要

实验性治疗的临床试验必须设计主要终点,直接衡量患者的临床获益。在许多疾病领域,公认的金标准主要终点可能需要多年才能成熟,这给临床研究的开展和质量带来挑战。人们越来越有兴趣使用短期替代终点来替代昂贵的长期临床试验终点;此类替代终点需要根据生物学合理性以及可靠预测未观察到的治疗对长期终点影响的能力来选择。已经提出了多种评估这种预测的统计方法;本文使用模拟研究,在事件发生时间替代终点用于事件发生时间真实终点的背景下,探索其中一种方法。这种两阶段荟萃分析连接函数方法已针对具有一个感兴趣事件的事件发生时间替代终点进行了广泛研究,但迄今为止尚未用于评估具有多个感兴趣事件的替代终点,例如那些直接纳入真实临床终点信息的替代终点。我们评估该方法对各种因素的敏感性,包括终点之间的关联强度、可用数据量以及删失的影响。特别是,我们考虑几乎没有数据可用于评估替代指标的情况。结果表明,两阶段荟萃分析连接函数方法在某些情况下表现良好,在实践中可能有用,但也显示出可能阻碍普遍使用的局限性。

相似文献

1
An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest.对用于评估由一个或多个感兴趣事件组成的事件发生时间替代终点的两阶段元分析Copula建模方法的研究。
Pharm Stat. 2017 Sep;16(5):322-333. doi: 10.1002/pst.1812. Epub 2017 May 19.
2
Assessment of the information theory approach to evaluating time-to-event surrogate and true endpoints in a meta-analytic setting.评估信息理论方法在荟萃分析中评估时间事件替代和真实终点的应用。
Pharm Stat. 2021 Mar;20(2):335-347. doi: 10.1002/pst.2080. Epub 2020 Nov 3.
3
surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.surrosurv:用于在随机临床试验个体患者数据荟萃分析中评估失效时间替代终点的 R 包。
Comput Methods Programs Biomed. 2018 Mar;155:189-198. doi: 10.1016/j.cmpb.2017.12.005. Epub 2017 Dec 13.
4
A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.一种使用二元替代终点来预测干预对真实终点影响的简单荟萃分析方法。
Biostatistics. 2006 Jan;7(1):58-70. doi: 10.1093/biostatistics/kxi040. Epub 2005 Jun 22.
5
Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data.使用中介分析和荟萃分析数据验证时间事件替代终点。
Biostatistics. 2023 Dec 15;25(1):98-116. doi: 10.1093/biostatistics/kxac044.
6
Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.贝叶斯调整后的 R2 用于临床试验中替代时间到事件终点的荟萃分析评估。
Stat Med. 2012 Apr 13;31(8):743-61. doi: 10.1002/sim.4416. Epub 2011 Dec 9.
7
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.癌症临床试验实例中的替代终点统计评估。
Biom J. 2016 Jan;58(1):104-32. doi: 10.1002/bimj.201400049. Epub 2015 Feb 12.
8
A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials.联合脆弱性-连接模型用于临床试验中失效时间替代终点的荟萃分析验证。
Biom J. 2021 Feb;63(2):423-446. doi: 10.1002/bimj.201900306. Epub 2020 Oct 1.
9
Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.消化系统肿瘤临床试验中总生存的替代终点:哪些候选物?临床医生和方法学家问卷调查。
BMC Cancer. 2010 Jun 10;10:277. doi: 10.1186/1471-2407-10-277.
10
Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.通过主分层法验证癌症临床试验中的替代终点及其在一项前列腺癌试验中的应用
Stat Med. 2017 Aug 30;36(19):2963-2977. doi: 10.1002/sim.7318. Epub 2017 May 8.

引用本文的文献

1
Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis.口咽部 p16 阳性鳞状细胞癌临床试验中的替代终点:一项个体患者数据荟萃分析。
Lancet Oncol. 2024 Mar;25(3):366-375. doi: 10.1016/S1470-2045(24)00016-0.
2
Surrogate endpoint evaluation using data from one large global randomized controlled trial.利用来自一项大型全球随机对照试验的数据评估替代终点。
BMC Med Inform Decis Mak. 2021 May 20;21(1):164. doi: 10.1186/s12911-021-01516-8.
3
A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.
一项关于使用荟萃分析报告替代终点评估的系统评价与建议
JNCI Cancer Spectr. 2019 Feb 6;3(1):pkz002. doi: 10.1093/jncics/pkz002. eCollection 2019 Mar.